Favorisce i processi di detossificazione del fegato

Inibisce la lipoperossidazione

Favorisce il mantenimento della funzionalità cellulare

Favorisce il recupero epatico nella patologia steatosica

Indicazioni e Modalità d'uso

Webinar 28 Settembre 2020

Ipertransaminasemia e NAFLD: approfondimenti e casi clinici

Medronys raccolta

Bibliografia

  1. Hajaghamohammadi A., Ziaee A., Raei R. The E-cacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Hepatitis Monthly Sett. 2008.
  2. Stephen A. Harrison, Sigurd Torgerson, Paul Hayashi et al. Vitamin E and vitamin C treatment improves brosis in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology (2003).
  3. Ales Vidlara, Jitka Vostalovab, Jitka Ulrichovab et al. The safety and e-cacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep.
  4. Farsi F., Mohammadshahi M., Alavinejad P. et al. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic In_x001D_ammation, and Adipokines in Patients Aected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2015 Jul 9.
  5. P. Ferenci , B. Dragosics , H. Dittrich. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul.